ATNT-07 FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB

Antzeko izenburuak

• Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
  nork: Angelova, Assia L., et al.
  Argitaratua: (2015)
• ET-21 COMBINATION OF INTRAVENOUS AND INTRACEREBRAL INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN A PHASE I/IIA CLINICAL TRIAL OF PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: PENETRATION OF H-1 VIRUS ACROSS THE BLOOD-BRAIN BARRIER
  nork: Geletneky, Karsten, et al.
  Argitaratua: (2014)
• Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
  nork: Angelova, Assia L., et al.
  Argitaratua: (2017)
• ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE
  nork: Geletneky, Karsten, et al.
  Argitaratua: (2018)
• Oncolytic parvoviruses: from basic virology to clinical applications
  nork: Marchini, Antonio, et al.
  Argitaratua: (2015)